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Abstract 
A variety of therapeutic options are now available for advanced renal cell cancer, in-
cluding  antiangiogenic  and  anti-mTOR  agents.  Allogeneic  hematopoietic  stem  cell 
transplantation, through its graft-versus-tumor effect, can induce clinical responses and 
prolonged survival in selected cytokine-refractory patients. However, the still relevant 
transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to 
its widespread use. 
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Allogeneic hematopoietic stem cell transplanta-
tion  from  a  compatible  donor  has  been  utilized  as 
adoptive  immunotherapy  in  metastatic,  cyto-
kine‐refractory  renal  cell  cancer  (RCC).  Since  2000, 
several  investigators  have  established  that  RCC  is 
susceptible  to  a  graft‐versus‐tumor  effect:  they  re-
ported that patients with renal cancer may have par-
tial  or  complete  disease  responses,  in  the  20‐40% 
range,  after  allogeneic  transplantation  following  a 
reduced‐intensity regimen (Table 1).  
 
 
Table 1. Major series of allografting for RCC 
  No. Patients  TRM %  Response rate %   aGvHD %  Prognostic factors 
NIH (2)   75   8   38   50   Limited number of metastatic sites 
Exclusive lung metastases 
Clear-cell histology  
Slow progressive disease  
Marseille (3)   32   6   16   -   Non-progressive disease at transplant  
Milano (4)   25   16   20   45   C-Reactive Protein 
Number of CD34+ infused  
Non progressive disease at +90 after transplant  
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In the seminal study1, 19 patients who had failed 
other forms of immunotherapy (mainly recombinant 
interleukin‐2  and/or  interferon‐alpha)  received  al-
lo‐SCT from an HLA identical sibling after reduced 
intensity  conditioning  (RIC)  including  cyclophos-
phamide and fludarabine. The response rate was 53% 
in these previously treated patients. Childs et al. later 
updated their results
2
: 74 patients with a median of 
two  metastatic  sites  have  been  transplanted.  Sus-
tained engraftment was achieved in 74/75 patients. 
Overall, 38% of patients have had radiographic evi-
dence of tumor regression (27% PR, 9% CR) with re-
sponses  occurring  at  a  median  of  day  +160  from 
transplant  (range  30‐425).  Tumor  responses  (fre-
quently  preceded  by  tumor  progression)  occurred 
sometimes after the administration of post transplant 
interferon‐alpha, even in patients who had previously 
failed this treatment. In a few cases, responses were 
durable. Acute and chronic graft‐versus‐host disease 
(GVHD) were observed in approximately 50% of pa-
tients. Death from TRM occurred in 8% of patients, 
half  of  whom  died  from  complications  related  to 
GVHD.  Several  prognostic  factors  were  associated 
with response, including: a limited number of meta-
static sites, exclusive lung metastases, clear cell his-
tology and “slow” progressive disease. Liver metas-
tases appeared to be a negative prognostic factor (11% 
response rate in those transplanted with liver metas-
tasis),  while  lung  metastasis  was  a  positive  factor 
(55% response rate). Responses in non‐clear histology, 
including papillary tumors were not observed. 
The group of Institut Paoli Calmettes reported 
thirty-two  cytokine-refractory  patients  (age:  45 
[17‐61]),  who  received  the  same  reduced  intensity 
conditioning  [Fludarabine  (150mg/msq),  Busulfan 
(8mg/kg)  and  Thymoglobulin  (2,5mg/kg)  or  TLI 
(1Cgy)] from a HLA‐identical sibling (BM: 9%; PBSC: 
91%)  followed  by  Cyclosporine  as  post‐transplant 
immunosuppression3. Prior to allo‐SCT a median of 2 
lines of treatment (1‐3) were administered over a pe-
riod of 650 days (164‐6964). At time of transplant, all 
pts had measurable disease with a median of 2 meta-
static sites (1‐4) (lung: 87%; bone: 41%; liver: 12 % and 
lymph node involvement: 28%): according to RECIST 
criteria, 21 pts (66%) had progressive disease (PD) and 
11 pt (34%) had non progressive disease (NPD) (10 
stable, 1 partial remission [PR]). Two of the 32 pts (6%) 
died  from  treatment  related  complications.  Four  of 
them achieved PR at days 90-180, 1 pt achieved com-
plete remission (CR) at day 270, with an objective re-
sponse  (OR)  rate  of  16%.  Twenty  seven  pts  finally 
died of disease progression for a 2-year overall sur-
vival (OS) rate of 21% (11‐39). Results are dramatically 
different  according  to  pts  disease  status  at  time  of 
transplant. While outcome is uniformly poor for pts 
with PD, pts with NPD achieved a 36% OR rate with 5 
pts (55%) surviving more than 2 years and 3 pts (27%) 
surviving more than 3 years. This analysis confirms 
the  low  treatment‐related  mortality  after  RIC‐based 
allo‐SCT. However, patients with rapidly progressive 
RCC do not benefit from this approach, emphasizing 
the need for selecting pts with slow disease progres-
sion kinetics or even less advanced disease to further 
improve transplant outcome.  
Recently,  the  Milano  group  published  a 
long‐term follow‐up of patients who have undergone 
allograft  for  cytokine-refractory  RCC:  Twenty‐five 
patients  received  a  reduced‐intensity  allograft  from 
an  HLA‐identical  sibling  donor  after  a  thiotepa, 
fludarabine  and  cyclophosphamide  conditioning 
regimen,  and  a  cyclosporine‐based  GVHD  prophy-
laxis.  One‐year  overall  survival  was  48%,  and 
five‐year OS was 20%. At a median observation time 
of 65 months, five patients are alive, one in CR, one in 
PR and three with stable disease. Survival of patients 
at  favorable/intermediate‐risk  according  to  the 
MSKCC score that underwent allografting was better 
in comparison to the survival predicted by historical 
controls.  They  concluded  that  20%  of  cyto-
kine‐refractory RCC patients are alive long‐term after 
allografting, and that transplantation is able to induce 
long‐term  disease  control  in  a  fraction  of  relapsed 
RCC patients
4
. 
The  introduction  in  the  clinic  of  molecularly 
targeted  agents  that  interfere  with  neoangiogenesis, 
both monoclonal antibodies and small tyrosine‐kinase 
inhibitor  molecules  (e.g.,  sunitinib,  sorafenib, 
bevacizumab), has considerably decreased the use of 
allogeneic  transplantation.  After  the  clinical  experi-
ence of the last ten years, there are still a number of 
open questions on this therapeutic procedure: 
1)  Is  the  GVT  effect  still  occurring  after  an-
ti-angiogenic (i.e., TKI, VEGF) and/or mTOR inhibi-
tion therapies? 
2) Is there a therapeutic window for allograft af-
ter first- or second-line therapies for RCC? 
3) Can we envisage clinical strategies for adop-
tive immunotherapy in RCC? 
Much of the future clinical work in this area will 
depend on the answers to these questions. 
Antigen discovery is an intriguing output of al-
lograft in RCC, that can have therapeutic implications. 
Experimental evidence suggests that donor‐derived T 
cells  and  NK  cells  are  the  main  mediators  of  the 
graft‐versus‐RCC effect upon allogeneic HSCT. Isola-
tion  of  CD8+
 
CTL  clones  recognizing  several  target 
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patibility  antigens  on  RCC  cells;  a  peptide  epitope 
derived from human endogenous retrovirus type E; 
the tumor‐associated antigen encoded by the Wilms 
tumor  1  gene)  has  increased  our  knowledge  of  the 
disease  biology,  and  has  opened  the  possibility  of 
antigen‐specific  adoptive  cell  therapy.  Though  not 
curative, novel targeted agents may be combined with 
allogeneic transplantation or with adoptive cell ther-
apy to maximize the chances of cure of RCC. 
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